Search clinical trials for: Lumacaftor-Ivacaftor treatment

Total 11190 results

Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Spain, Germany, Italy, Austria, Belgium, Denmark
Postgraduate Institute of Dental Sciences Rohtak

Unknown

Comparision of Non Surgical Retreatment and Endodontic Surgery of Failed Root Canal Treated Teeth

Periapical Periodontitis | Root Canal Therapy

India
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

Australia
Ulthera, Inc

Completed

Feasibility Study: Evaluation of the Treatment of Striae Using Ultherapy® in Combination With Laser Treatment

Scars | Striae

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Judge Baker Children's Center
University of Illinois at Chicago; University of Hawaii; MacArthur Foundation

Completed

The Clinic Treatment Project (CTP)

Depression | Problem Behavior | Anxiety

United States
Istanbul University - Cerrahpasa (IUC)

Completed

The Effect of Motor Imagery in Patients With Radius Distal End Fracture

Distal Radius Fracture

Turkey
Region Skane
Lund University

Recruiting

ACUTE-Acute Surgical Care- Risk Factors and Outcomes for Patients in Need of Acute Surgical Care (ACUTE)

Complication of Surgical Procedure | Risk Factors | Complication of Treatment | Complication of Anesthesia | Long Term Effects After Emergency Surgery | Long Term Effects After GI Bleeding

Sweden
Sahlgrenska University Hospital, Sweden

Recruiting

Local Recurrence Due to Rectal Cancer in Sweden (LERIS)

Rectal Neoplasms

Sweden
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
Rennes University Hospital

Recruiting

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release (DIPLOID)

Pharmacokinetics

France
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Phase II Clinical Trial Scheme of Ganoderma Lucidum Spore Powder for Postoperative Chemotherapy of Osteosarcoma

Osteosarcoma
University of Chicago

Withdrawn

Single vs Multi-fraction SRS Patients on Immunotherapy (MIGRAINE)

Brain Cancer | Brain Metastases

United States
Medical University of South Carolina
Vertex Pharmaceuticals Incorporated

Completed

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

Cystic Fibrosis
Pennington Biomedical Research Center

Enrolling by invitation

Effect of Physiologic Insulin Administration on Cognition

Alzheimer Disease

United States
Children's Hospital of Philadelphia
Vertex Pharmaceuticals Incorporated

Completed

Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects

Cystic Fibrosis

United States
University of Alabama at Birmingham
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Vertex...

Withdrawn

The Multicenter Topic Trial

Chronic Obstructive Pulmonary Disease
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

Cystic Fibrosis

United Kingdom, United States, Canada
University of Edinburgh
NHS Lothian

Completed

Pain Following Root Canal Treatment (PfRCT)

Assessment of Pain After Root Canal Treatment

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Netherlands, United Kingdom, Germany, Portugal
Children's Hospital of Philadelphia

Completed

Distal Radius Buckle Fracture RCT

Distal Radius Fracture

United States
University of Alabama at Birmingham

Completed

TOPIC Trial for COPD

Chronic Obstructive Pulmonary Disease

United States
University of Cadiz

Completed

Treatment of Cervical Syndrome With Physium Therapy

Cervical Syndrome

Spain
Mayo Clinic

Completed

LLLT for Reducing Waste Circumference and Weight (LLLT)

Weight Loss

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-770 Expanded Access Program

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects

In Development for Cystic Fibrosis

Czech Republic, Slovakia
University of Alabama at Birmingham

Recruiting

Personalized Theratyping Trial

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation (KONTINUE)

Cystic Fibrosis

United States, France, Belgium, United Kingdom
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation

Cystic Fibrosis

United States, United Kingdom, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)

Cystic Fibrosis

United States, Canada, Australia, Ireland, France, United Kingdom, Germany, Czech Republic
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation (ENVISION)

Cystic Fibrosis

United States, Australia, Canada, France, Germany, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-770 on Desipramine

In Development for Cystic Fibrosis

United States
Italian Sarcoma Group

Recruiting

Study on Clinical Features and Outcomes of Breast Sarcoma (Breast-Sarc)

Breast Sarcoma

Italy
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Rollover Study of VX-770 in Cystic Fibrosis Subjects

Cystic Fibrosis

United States, France, United Kingdom, Germany, Canada, Czech Republic, Ireland, Australia
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT) (KONDUCT)

Cystic Fibrosis

United States, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Cystic Fibrosis

Israel
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation (KONNECTION)

Cystic Fibrosis

United States, France, Belgium
Ulthera, Inc

Completed

Feasibility Study: Ulthera System for the Treatment of Rosacea

Erythematotelangiectatic Rosacea

Canada
Italian Sarcoma Group

Completed

Study in Low Risk Gastrointestinal Stromal Tumor (GISTs) (RetroGIST)

GIST

Italy
KLOX Technologies Inc.

Unknown

Assessment of the Evolution of Wound Biomarkers in Venous Leg Ulcers Treated With KLOX Biophotonic System

Venous Leg Ulcer

Italy
Concert Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects

Healthy

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Ireland, United Kingdom
Eloxx Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

Cystic Fibrosis

Israel, Australia, Germany

Search clinical trials for: Lumacaftor-Ivacaftor treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations